Apixaban for Stroke Prevention in Atrial Fibrillation: Why are Event Rates Higher in Clinical Practice than in Randomized Trials?—A Systematic Review

Tim A. C. de Vries1,2,3 ▪ Jack Hirsh4,5 ▪ Ke Xu1,6 ▪ Imaad Mallick1 ▪ Vinai C. Bhagirath4,5 ▪ John W. Eikelboom1,4,5 ▪ Jeffrey S. Ginsberg4,5 ▪ Paul C. Kruger1,7 ▪ Noel C. Chan1,4,5

1 Population Health Research Institute, Hamilton, Ontario, Canada
2 Department of Cardiology, Rijnstate Hospital, Arnhem, Gelderland, The Netherlands
3 Department of Cardiology, Amsterdam University Medical Centers/University of Amsterdam, Amsterdam, North Holland, The Netherlands
4 Thrombosis and Atherosclerosis Research Institute, Hamilton, Ontario, Canada
5 Department of Medicine, McMaster University, Hamilton, Ontario, Canada
6 Department of Cardiology, Shanghai Jiao Tong University, Shanghai, China
7 Department of Haematology, Fiona Stanley Hospital, Murdoch, Western Australia, Australia

Address for correspondence Noel C. Chan, MBBS, Thrombosis and Atherosclerosis Research Institute, DBCVRI, McMaster University, 237 Barton St East, Hamilton, ON L8S 4L8, Canada (e-mail: noel.chan@taari.ca).

Abstract

Background Recent reports suggest an important contribution from frequent off-label use of apixaban 2.5 mg twice daily to the higher rates of thromboembolic events observed in observational studies (OSs) relative to in randomized controlled trials (RCTs), and consequently, advocate against such use in all patients.

Objectives To examine factors contributing to the higher thromboembolic event rates, we estimated the prevalence of off-label use in contemporary practice, and compared patient characteristics and rates of stroke/systemic embolism, major bleeding, and mortality by apixaban dose and by study design in a systematic review and meta-analysis.

Results and Discussion We identified 18 OSs and 2 RCTs that included 155,228 and 11,928 patients, respectively. Patients in OSs more often received apixaban 2.5 mg twice daily (31.3% vs. 5.1%), were older (mean age 73.8 vs. 69.8 years), and had higher CHA2DS2-VASc scores (mean 3.6 vs. 2.9) versus those in RCTs. We observed a consistent pattern of higher rates of thromboembolic events, bleeding, and mortality in patients treated with 2.5 versus 5 mg twice daily apixaban in both OSs and RCTs.

Conclusion The higher risk profiles of patients in OSs versus RCTs, and higher rates of both bleeding and mortality not attributable to thromboembolism in patients treated with apixaban 2.5 versus 5 mg twice daily suggest that differences in patient characteristics are additional important contributors to the higher than expected thromboembolic event rates in clinical practice.
Introduction

Apixaban, a direct acting oral anticoagulant, has been evaluated for stroke prevention in atrial fibrillation (AF) in two phase III trials: AVERROES (apixaban vs. aspirin) and ARISTOTLE (apixaban vs. warfarin). In both trials, apixaban was dosed according to an explicit dosing strategy, which was informed by results of pre-phase III studies. The standard dose of 5 mg twice daily was given to most patients and a reduced dose of 2.5 mg twice daily to those who met at least two of three clinical characteristics (age ≥ 80 years, body weight ≤ 60 kg, and creatinine level ≥ 133 µmol/L), known as the ABC criteria which are independently associated with increased apixaban levels. In AVERROES, apixaban proved to be more effective than aspirin in preventing the composite of stroke and systemic embolism events (S/SEE) and did not result in more major bleeding, whereas in ARISTOTLE, it was shown to be both more effective and safer than warfarin.1,2

Now, several years after the approval of apixaban by regulatory authorities, several large health databases and registries report rates of thromboembolic events and bleeding with apixaban that are higher than those observed in the earlier phase III randomized controlled trials (RCTs).1–21 particularly in those treated with the 2.5-mg dose.6,7,11,16,18,21 These observations are in keeping with the generally accepted view that, because of different criteria used for patient selection, rates of adverse events are higher in observational studies than in RCTs.22

On the other hand, recent data provide another potential treatable cause for the higher rates of thromboembolic events in patients prescribed apixaban in clinical practice. Thus, several observational studies have reported that the 2.5-mg dose of apixaban is used much more frequently in clinical practice than in RCTs,1,2,7,9,10,12,13,15,16,19,20 that approximately 50% of patients who receive this dose do not meet two or more of the ABC criteria (i.e., off-label use),23–31 and that such use is associated with an increased risk of thromboembolic events.23,29,32–34 On these grounds, several authors and guidance documents advocate against the off-label use of the 2.5-mg dose in all patients.23,29,32–36

Based on the above considerations, we sought to determine the factors contributing to the higher thromboembolic event rates. To achieve this aim, we estimated the prevalence of off-label use in contemporary practice, and compared baseline characteristics and rates of thromboembolic events, bleeding, and death in patients with AF by dose of apixaban (2.5 vs. 5 mg twice daily) and by study design (observational studies vs. RCTs).

Methods

We performed a systematic search for RCTs and observational studies reporting on clinical outcomes in AF patients taking apixaban for the prevention of ischemic stroke using the Ovid MEDLINE and the PubMed Central databases from the inception of these databases up to and including October 2019. The search strategy included the following keywords: “apixaban” AND “atrial fibrillation” AND “thromboembolism” OR “embolism” OR “stroke” OR “haemorrhage” OR “hemorrhage” OR “bleeding” OR “mortality” OR “death.” English publications that reported on absolute annualized rates of thromboembolic events, bleeding, and/or death in patients with AF taking apixaban were eligible for inclusion. The search was supplemented by screening the reference lists of recent systematic reviews on similar topics identified from the initial search. We excluded studies enrolling less than 1,000 patients to minimize small-study effect. After deduplication, all hits were screened for eligibility in duplication. In the instance of disagreement, the final decision was determined by a third reviewer.

Assessing the quality of evidence of meta-analyses of observational studies reporting on event rates is less well established than for those of RCTs reporting on the treatment effect of interventions.32 Through iterative discussion, we developed an instrument to categorize studies according to their risk of bias and adopted the Grading of Recommendations Assessment, Development and Evaluation system.38 Accordingly, we rated the quality of evidence for each clinical outcome (∼ Supplementary Material S1, available in the online version). All quality assessments were performed by two reviewers and any disagreement resolved by consensus with a third.

Articles reporting on the same database were included but we avoided double counting by using data of interest from the more comprehensive publication (∼ Supplementary Material S1: ∼ Tables 1 and 2, and ∼ Supplementary Material S2 and S3, available in the online version). For each study, we extracted data for baseline characteristics (e.g., age and CHA2DS2-VASc score), dosing practice (i.e., the proportion of patients receiving the 2.5- or 5-mg dose), and clinical adverse outcomes (i.e., S/SEE, ischemic stroke, major bleeding, intracranial hemorrhage [ICH], and all-cause death). All extractions were performed by the primary author, and any errors corrected by a secondary author by reviewing the original publications. We presented the data for baseline characteristics and dosing practice as weighted pooled estimates for means (according to study size) and standard deviations (SDs),39 or as proportions.40–42 In the instance that means were not reported in the original study, we used the reported medians and (interquartile) ranges to estimate means and SDs (∼ Supplementary Material S2, available in the online version).43

By taking time of follow-up of each study into consideration, we estimated the annual number of events for each clinical outcome prior to pooling (∼ Supplementary Material S2, available in the online version). To calculate a pooled estimate for each outcome, we used the Freeman–Tukey transformation under a fixed effect model, or a random effects model if significant inconsistency was observed (∼ Supplementary Material S1: ∼ Tables 6 and 8, available in the online version).40–42

To compare clinical outcomes between RCTs and descriptive studies, we reported a relative risk (RR) and a 95% confidence interval (CI) for apixaban-treated patients, irrespective of dose, and for patients treated with either 2.5 or
Results

Our original search yielded 3,186 publications, and an additional 61 by screening reference lists. Of these, 1,593 were unique publications, most of which \((n = 1,504; 94.4\%)\) were excluded after screening titles and/or abstracts. Another 69 were excluded due to various reasons after full paper assessment, including presence of duplicate datasets. Overall, we included 18 observational studies and 2 RCTs (AVERROES and ARISTOTLE) in our analyses.

Table 1 describes the clinical characteristics of the patients who were treated with either apixaban or a VKA in the two types of studies. Patients treated with apixaban in observational studies were older (mean age 73.8 vs. 69.8 years), had higher CHA2DS2-VASc scores (mean 3.6 vs. 2.9), and were far more likely to receive the reduced dose (31.3% vs. 5.1%), than those enrolled in RCTs.\(^4\),\(^7\),\(^9\),\(^10\),\(^12\),\(^13\),\(^15\),\(^17\),\(^19\),\(^20\),\(^47\)

Apixaban-treated patients prescribed 5 mg were older in observational studies than in RCTs (mean age 70.5 vs. 68.6 years),\(^7\),\(^9\),\(^11\),\(^14\),\(^16\),\(^21\),\(^48\) whereas for those on 2.5 mg no important difference was observed (mean age 83.1 vs. 83.6 years).\(^7\),\(^9\),\(^13\),\(^16\),\(^21\),\(^48\)

We were unable to find data on CHA2DS2-VASc scores per dosing regimen of apixaban for patients enrolled in the RCTs. Similarly, compared with patients treated with a VKA in RCTs, VKA-treated patients included in observational studies were older (mean age 76.8 vs. 69.7 years), and had higher CHA2DS2-VASc scores (mean 3.7 vs. 2.9).\(^2\),\(^4\),\(^7\),\(^9\),\(^15\),\(^16\),\(^20\)

Table 2 shows the rates of S/SEE, ischemic stroke, major bleeding, ICH, and mortality of patients treated with either apixaban or a VKA in observational studies, compared with those in RCTs. Patients treated with apixaban in observational studies had higher rates of S/SEE (RR 1.62; 95% CI 1.19–1.64), major bleeding (RR 1.37; 95% CI 1.20–1.56), ICH (RR 1.61; 95% CI 1.17–2.20), and mortality (RR 1.91; 95% CI 1.73–2.11) than those treated with apixaban in RCTs.\(^1\),\(^10\),\(^12\),\(^13\),\(^15\),\(^17\),\(^19\),\(^20\)

Patients treated with apixaban 5 mg twice daily in observational studies had higher rates of S/SEE (RR 1.40; 95% CI 1.14–1.73), major bleeding (RR 1.34; 95% CI 1.15–1.56), and mortality (RR 1.16; 95% CI 1.00–1.35) than those in RCTs.\(^6\),\(^7\),\(^11\),\(^14\),\(^16\),\(^21\)

A similar trend was observed for those treated with apixaban 2.5 mg twice daily: rates of S/SEE (RR 2.10; 95% CI 0.95–4.67), major bleeding (RR 1.18; 95% CI 0.70–1.99), and mortality (RR 1.19; 95% CI 0.89–1.58) were higher compared with patients on the same dose in RCTs, but the difference did not reach statistical significance.\(^6\),\(^7\),\(^11\),\(^16\),\(^18\),\(^21\)

We were unable to obtain rates of ICH by dose of apixaban for patients enrolled in RCTs. The rates of ICH were similar (RR 1.08; 95% CI 0.86–1.36).\(^2\),\(^9\),\(^12\),\(^15\),\(^16\),\(^18\),\(^20\)

Table 3 shows the rates of S/SEE, ischemic stroke, major bleeding, ICH, and mortality of patients on 2.5 mg twice daily apixaban compared with those on 5 mg twice daily, both in observational and in randomized studies. Regardless of study design, patients on 2.5 mg twice daily had much higher rates of thromboembolic events, bleeding, and death than those treated with 5 mg twice daily (1.26– to 3.16-fold).\(^6\),\(^7\),\(^11\),\(^14\),\(^16\),\(^18\),\(^21\)

Moreover, an absolute risk difference between both dosing regimens of +1.4%/year, +1.0%/year, +0.3%/year, and +9.6%/year for S/SEE, major bleeding, ICH, and all-cause death, respectively, was observed in observational studies;\(^6\),\(^7\),\(^11\),\(^14\),\(^16\),\(^18\) and a +0.4%/year for S/SEE, +1.2% for major bleeding, and +6.8%/year for mortality in RCTs.\(^21\)

Abbreviations: CHA2DS2-VASc (a score that estimates the annual risk of stroke for patients with atrial fibrillation), Congestive heart failure, Hypertension, Age ≥ 75 years (2 points), Diabetes mellitus, Prior Stroke or TIA or thromboembolism (2 points), Vascular disease, Age between 65–74 years, Sex category; SD, standard deviation.

Note: Values represent the absolute numbers, percentages, or means ± standard deviations.

*Derived from a study of the ARISTOTLE trial.\(^47\)

*Derived from a study of the AVERROES trial.\(^48\)
Our results confirm other reports and show that apixaban-treated patients with AF enrolled in observational studies (1) have higher rates of thromboembolic events, as well as of bleeding and death; (2) have baseline characteristics that put them at higher risk of both thromboembolic events and bleeding; and (3) are more frequently treated with the 2.5-mg dose than those enrolled in RCTs, of which about half (57.2%, 95% CI: 45.9–68.2%) is used off-label according to results of contemporaneous observational studies (►Supplementary Material S2: ►Table 17, and S3: ►Figs. 33 and 34, available in the online version).

In addition, our results indicate that in both observational and randomized studies, patients treated with the lower dose of apixaban demonstrate a consistent pattern of higher rates of both bleeding and mortality in addition to a higher rate of thromboembolic events.

Several authors and guidance documents have advocated against the off-label use of the 2.5-mg dose,23,29,32–36 on the grounds that it is an important cause of the excess of S/SEE reported in observational studies and daily clinical practice.23,29,32–34 However, our findings provide an additional explanation and suggest that enrolment of patients with worse risk profiles in observational studies (vs. RCTs) is an important contributor to the high rates of thromboembolic events in those receiving the 2.5-mg dose of apixaban. We base our suggestion on the following observations.

First, patients receiving the 2.5-mg dose in observational studies had the worst prognostic characteristics of all four groups analyzed (►Table 1). Second, not only were the rates

### Table 2 Risks of thromboembolism, bleeding, and death in observational studies compared with in randomized controlled trials

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>Observational studies</th>
<th>Randomized controlled trials</th>
<th>Relative risk (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No. with events (sample size)</td>
<td>%/y</td>
<td>No. with events (sample size)</td>
</tr>
<tr>
<td>Apixaban, either dose</td>
<td>S/SEE</td>
<td>2,050 (108,765)</td>
<td>1.8</td>
</tr>
<tr>
<td></td>
<td>Ischemic stroke</td>
<td>2,283 (141,527)</td>
<td>1.6</td>
</tr>
<tr>
<td></td>
<td>Major bleedinga</td>
<td>3,843 (142,955)</td>
<td>2.6</td>
</tr>
<tr>
<td></td>
<td>ICH</td>
<td>807 (145,863)</td>
<td>0.6b</td>
</tr>
<tr>
<td></td>
<td>All-cause death</td>
<td>3,037 (45,263)</td>
<td>6.6</td>
</tr>
<tr>
<td>Apixaban, 5 mg twice daily</td>
<td>S/SEE</td>
<td>960 (61,179)</td>
<td>1.5</td>
</tr>
<tr>
<td></td>
<td>Ischemic stroke</td>
<td>727 (60,118)</td>
<td>1.6³</td>
</tr>
<tr>
<td></td>
<td>Major bleedinga</td>
<td>1,811 (64,779)</td>
<td>2.8</td>
</tr>
<tr>
<td></td>
<td>ICH</td>
<td>277 (65,581)</td>
<td>0.4</td>
</tr>
<tr>
<td></td>
<td>All-cause death</td>
<td>413 (11,010)</td>
<td>3.5³</td>
</tr>
<tr>
<td>Apixaban, 2.5 mg twice daily</td>
<td>S/SEE</td>
<td>760 (25,556)</td>
<td>2.9</td>
</tr>
<tr>
<td></td>
<td>Ischemic stroke</td>
<td>488 (20,409)</td>
<td>2.2</td>
</tr>
<tr>
<td></td>
<td>Major bleedinga</td>
<td>1,103 (28,250)</td>
<td>3.8</td>
</tr>
<tr>
<td></td>
<td>ICH</td>
<td>202 (29,477)</td>
<td>0.7</td>
</tr>
<tr>
<td></td>
<td>All-cause death</td>
<td>1,461 (12,241)</td>
<td>13.1³</td>
</tr>
<tr>
<td>Vitamin K antagonists</td>
<td>S/SEE</td>
<td>5,589 (225,971)</td>
<td>2.5</td>
</tr>
<tr>
<td></td>
<td>Ischemic stroke</td>
<td>5,558 (311,567)</td>
<td>1.8</td>
</tr>
<tr>
<td></td>
<td>Major bleedinga</td>
<td>14,643 (339,980)</td>
<td>4.1</td>
</tr>
<tr>
<td></td>
<td>ICH</td>
<td>3,045 (354,248)</td>
<td>0.8³</td>
</tr>
<tr>
<td></td>
<td>All-cause death</td>
<td>9,691 (163,084)</td>
<td>5.8</td>
</tr>
</tbody>
</table>

Abbreviations: %/y, number of events per 100 patient-years; CI, confidence interval; ICH, intracranial hemorrhage; NR, not reported; S/SEE, the composite of stroke and systemic embolism events.

*The definitions of major bleeding varied among the observational studies. For the precise definitions of major bleeding used by the individual studies, please refer to the respective articles (see ►Supplementary Material S2: ►Tables 13–16).

*Pooled rate derived from the random effects model due to serious inconsistency (see ►Supplementary Material S1: ►Tables 6 and 8).

### Discussion

Our results confirm other reports and show that apixaban-treated patients with AF enrolled in observational studies (1) have higher rates of thromboembolic events, as well as of bleeding and death; (2) have baseline characteristics that put them at higher risk of both thromboembolic events and bleeding; and (3) are more frequently treated with the 2.5-mg dose than those enrolled in RCTs, of which about half (57.2%, 95% CI: 45.9–68.2%) is used off-label according to results of contemporaneous observational studies (►Supplementary Material S2: ►Table 17, and S3: ►Figs. 33 and 34, available in the online version). In addition, our results indicate that in both observational and randomized studies, patients treated with the lower dose of apixaban demonstrate a consistent pattern of higher rates of both bleeding and mortality in addition to a higher rate of thromboembolic events.

Several authors and guidance documents have advocated against the off-label use of the 2.5-mg dose,23,29,32–36 on the grounds that it is an important cause of the excess of S/SEE reported in observational studies and daily clinical practice.23,29,32–34 However, our findings provide an additional explanation and suggest that enrolment of patients with worse risk profiles in observational studies (vs. RCTs) is an important contributor to the high rates of thromboembolic events in those receiving the 2.5-mg dose of apixaban. We base our suggestion on the following observations.

First, patients receiving the 2.5-mg dose in observational studies had the worst prognostic characteristics of all four groups analyzed (►Table 1). Second, not only were the rates
of thromboembolic events higher but those of major bleeding and mortality were also higher in observational studies compared with RCTs, which was evident for both apixaban- and VKA-treated patients (→ Table 2). Moreover, the higher events rates for all three outcomes were consistently seen with both the 5- and 2.5-mg doses of apixaban (→ Table 2). Finally, relative to those taking the full dose, patients treated with the lower dose not only had higher rates of thromboembolic events but also higher rates of bleeding and a strikingly greater risk of mortality that cannot be accounted for by the difference in rates of thromboembolic events. The higher bleeding rate as well as the mortality unrelated to thromboembolism cannot be attributable to underdosing and therefore to off-label use of the 2.5-mg dose (→ Table 3). Thus, although the design of our study does not allow us to quantify the relative contributions of underdosing and patient-related factors, our results suggest that the inclusion of higher risk patients in observational studies is an important contributor to the increased rates of S/SEE in patients who are treated with 2.5 mg apixaban.

Pharmacokinetic and clinical studies that established and validated the ABC criteria excluded many patients at high risk of bleeding who were included in the observational studies and are treated with apixaban in clinical practice.1,2,21,48 Given the differences between the populations, it is therefore unclear whether some patients seen in clinic, who are deemed to be at very high risk of bleeding or overexposure to apixaban, would be better served if they were treated with an on-label 5 mg dose or off-label 2.5 mg dose of apixaban. Until we have more data, physicians will have to use their clinical judgment when dosing apixaban in these patients.

**Strengths and Limitations**

The main strengths of our study is that we performed a systematic search for observational and randomized studies, compared the differences in baseline characteristics and rates of most important adverse outcomes for patients with AF (S/SEE, ischemic stroke, major bleeding, ICH, and mortality) between these two study designs, and by apixaban dose.

The main limitations of our study are that: (1) our conclusion is based on analyses of nonrandomized data; (2) the indirect comparisons included only two randomized studies; (3) the proportion of off-label use was not reported by individual observational studies included in our meta-analysis, and we relied on data from contemporaneous observational studies to obtain the best estimates of the prevalence of off-label use; (4) a modest number of patients were prescribed the 2.5-mg dose of apixaban in the RCTs (n = 596), and of these, we were only able to derive data on clinical characteristics and event rates from 145 (a substudy of AVERROES),48 and 428 patients (ARISTOTLE),21 respectively; and (5) our design does not provide definitive information on the criteria that should be used in clinical practice to select patients for apixaban dose reduction. Only a well-designed RCT would provide the required information.

**Conclusion**

The higher risk profiles of patients in clinical practice compared with RCTs, and higher rates of both bleeding and mortality not attributable to thromboembolism in patients treated with apixaban 2.5 mg twice daily compared with

<table>
<thead>
<tr>
<th>Outcome</th>
<th>No. with events (sample size)</th>
<th>%/y</th>
<th>No. with events (sample size)</th>
<th>%/y</th>
<th>Relative risk (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>S/SEE</td>
<td>760 (25,556)</td>
<td>2.9</td>
<td>960 (61,179)</td>
<td>1.5</td>
<td>1.90 (1.73–2.08)</td>
</tr>
<tr>
<td>Ischemic stroke</td>
<td>488 (20,409)</td>
<td>2.2</td>
<td>727 (60,118)</td>
<td>1.6</td>
<td>1.98 (1.77–2.22)</td>
</tr>
<tr>
<td>Major bleeding</td>
<td>1,103 (28,250)</td>
<td>3.8</td>
<td>1,811 (64,779)</td>
<td>2.8</td>
<td>1.40 (1.30–1.50)</td>
</tr>
<tr>
<td>ICH</td>
<td>202 (29,477)</td>
<td>0.7</td>
<td>277 (65,581)</td>
<td>0.4</td>
<td>1.62 (1.35–1.94)</td>
</tr>
<tr>
<td>All-cause death</td>
<td>1,461 (12,241)</td>
<td>13.1</td>
<td>413 (11,010)</td>
<td>3.5</td>
<td>3.16 (2.84–3.51)</td>
</tr>
</tbody>
</table>

---

Abbreviations: %/y, number of events per 100 patient-years; CI, confidence interval; ICH, intracranial hemorrhage; NR, not reported; S/SEE, the composite of stroke and systemic embolism events.

*The de...*
5 mg twice daily suggest that differences in patient characteristics are additional important contributors to the higher than expected thromboembolic event rates in clinical practice.

What is known about this topic?
- Rates of thromboembolic events in patients with atrial fibrillation prescribed apixaban are higher in observational studies than in the pivotal randomized trials.
- The 2.5-mg dose of apixaban is used much more frequently in clinical practice than in randomized trials, and approximately 50% of patients who receive this dose in clinical practice do not meet the labeled criteria for dose reduction. Recent reports associate off-label use of 2.5 mg apixaban with higher rates of thromboembolic events.
- Accordingly, there is a prevailing view that the off-label use of the 2.5-mg dose is an important cause of higher rates of thromboembolic events in observational studies relative to randomized studies, and consequently, that such use should be avoided in all patients.

What does this paper add?
- The higher risk profiles of patients in observational versus randomized studies, and higher rates of both bleeding and mortality not attributable to thromboembolism in patients treated with apixaban 2.5 mg twice daily versus 5 mg twice daily suggest that differences in patient characteristics are additional important contributors to the higher than expected thromboembolic event rates in clinical practice.

Acknowledgements
T.A.C.V. was supported by two educational scholarships: the Marco Polo Scholarship from the University of Groningen and the De Cock-Hadders scholarship from the De Cock-Hadders foundation. K.X. was supported by an educational grant from the China Scholarship Council. P.C.K. was supported by an educational grant from the Haematology Society of Australia and New Zealand. J.W.E. is the recipient of a midcareer award from the Heart and Stroke Foundation and holds the Jack Hirsh/Population Health Research Institute Chair in Thrombosis and Atherosclerosis. N.C.C. holds a McMaster University, Department of Medicine Internal Career Research Award.

References

Authors’ Contributions
T.A.C.V., J.H., V.C.B., J.W.E., J.S.G., P.C.K., and N.C.C. have contributed to the concept and design of the study. T.A.C.V., J.H., and N.C.C. developed the study protocol, designed, and coordinated the study. T.A.C.V., K.X., and N.C.C. developed the search strategy. T.A.C.V. and K.X. tailored the search strategy, performed the literature searches, and extracted the data. T.A.C.V. and K.X. performed the quality assessments, and any disagreement was resolved by N.C.C., T.A.C.V., J.H., V.C.B., J.S.G., J.W.E., and N.C.C. developed the initial analysis plan. T.A.C.V. and I.M. performed the analysis. T.A.C.V., J.H., and N.C.C. wrote the initial draft and subsequent iterations. All the other authors reviewed the drafts, provided critical comments, and revised the initial draft to produce the final manuscript.

Conflict of Interest
T.A.C.V. has received honoraria from Daiichi Sankyo, J.W.E. has received honoraria and research support from Astra-Zeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Janssen, Pfizer, Portola, and Sanofi. V.C.B. has received grants from Pfizer, Canada and honoraria from Bayer. N.C.C. has received honoraria from Bayer. Other authors report no conflicts of interests.
Higher Thromboembolic Event Rates in Apixaban Users with Atrial Fibrillation

21 Rose M, Beasley BN. Center for drug evaluation and research application number: 20215501g1s000 medical review(s). Published 2012. Updated December 17, 2012. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/20215501g1s000Medr.pdf. Accessed December 18, 2019
45 Altman DG. Confidence intervals for the number needed to treat. BMJ 1998;317(7168):1309–1312